<SEC-DOCUMENT>0001171843-26-002539.txt : 20260420
<SEC-HEADER>0001171843-26-002539.hdr.sgml : 20260420
<ACCEPTANCE-DATETIME>20260420060020
ACCESSION NUMBER:		0001171843-26-002539
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260420
FILED AS OF DATE:		20260420
DATE AS OF CHANGE:		20260420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		26873235

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_041926.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of April 2026</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39777</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Nanobiotix S.A.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>60 Rue de Wattignies 75012 Paris, France</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>&#160;</p><p>&#160;</p><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p>--><hr style="page-break-after: always;" noshade="noshade" /><p> <p>On April 20, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br /><a href="exh_991.htm">(c) Exhibit 99.1. Press release dated April 20, 2026</a></p><p></p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;Nanobiotix S.A.&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: April 20, 2026</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Bart Van Rhijn&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Bart Van Rhijn</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Chief Financial Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <ul type="disc"><li style="margin-top:6pt; margin-bottom:6pt;">Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(&#8220;LNP&#8221;)-delivered therapies related to rapid liver clearance</li><li style="margin-top:6pt; margin-bottom:6pt;">Pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA (&#8220;LNP-DNA&#8221;) designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nanoprimer</li></ul>  <p align="center"><em>Data presented at the 2026 Annual Meeting of the American Association for Cancer Research</em></p>  <p align="justify">PARIS and CAMBRIDGE, Mass., April  20, 2026  (GLOBE NEWSWIRE) -- <u>NANOBIOTIX</u> (Euronext: NANO - NASDAQ: NBTX - the &#8220;Company&#8221;), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of new preclinical data evaluating its Nanoprimer platform in sequence with lipid nanoparticle-delivered recombinant DNA (&#8220;LNP-DNA&#8221;) at the 2026 Annual Meeting of the American Association for Cancer Research (AACR).</p>  <p align="justify"><strong>POSTER #6389: Maximizing systemic LNP-DNA delivery for cancer-activated expression of Immunotherapy agents using Nanoprimer technology </strong></p>  <p align="justify"><u>Background</u></p>  <p align="justify">A key limitation common to LNP-DNA is rapid hepatic clearance via the mononuclear phagocyte system (&#8220;MPS&#8221;), which can reduce systemic bioavailability and tumor accumulation, as well as increase hepatic toxicity. In addition, LNP-DNA may trigger transient acute inflammation through activation of the cGAS/STING pathway.</p>  <p align="justify">In this evaluation, LNP-DNA vehicles designed for anti-tumor immunotherapy were administered with or without Nanobiotix Nanoprimer pre-treatment in a mouse model. Nanoprimer is designed to transiently occupy hepatic clearance pathways such as MPS to increase bioavailability and target accumulation, while reducing hepatic toxicity. Both agents were administered intravenously (IV).</p>  <p align="justify"><u>Key Observations</u></p>  <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Reduced hepatic exposure and toxicity:  <ul type="circle"><li style="margin-bottom:6pt; text-align:justify;">Decreased liver uptake of LNP-DNA and improved hepatic tolerability</li></ul>  </li><li style="margin-bottom:6pt; text-align:justify;">Improved systemic bioavailability:  <ul type="circle"><li style="margin-bottom:6pt; text-align:justify;">Increase in circulating levels of LNP-DNA</li></ul>  </li><li style="margin-bottom:6pt; text-align:justify;">Mitigation of inflammatory response:  <ul type="circle"><li style="margin-bottom:6pt; text-align:justify;">Attenuated activation of cGAS-STING pathway downstream targets</li></ul>  </li><li style="margin-bottom:6pt; text-align:justify;">Potentially broad applicability across LNP designs:  <ul type="circle"><li style="margin-bottom:6pt; text-align:justify;">Notably, these LNP-DNA formulations were specifically engineered for extrahepatic delivery, supporting the potential of the Nanoprimer to further optimize advanced delivery systems<br ><br ></li></ul>  </li></ul>  <p align="justify"><u>Conclusions</u></p>  <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">These data support further evaluation of Nanoprimer in sequence with innovative LNP-delivered therapies</li><li style="margin-bottom:6pt; text-align:justify;">Advanced LNP systems designed for extrahepatic delivery could potentially be further optimized to improve systemic bioavailability and reduce toxicity through sequencing with the Nanoprimer<br ><br ></li></ul>  <p align="justify">&#8220;We continue our dual path approach to the development of our next-wave Nanoprimer platform in which we are both pursuing external collaborations with partners developing innovative therapeutic candidates that are challenged by liver accumulation, as well as our own proprietary internal pipeline,&#8221; said Laurent Levy Nanobiotix Chief Executive Officer and Chairman of the Executive Board. &#8220;We are encouraged by these preclinical results, generated in collaboration with Earli, which further support our hypothesis that the Nanoprimer may improve therapeutic efficacy while mitigating toxicity when sequenced prior to the administration of advanced therapeutics such as LNP-DNA and an additional layer of proof of concept.&#8221;</p>  <p align="justify"><strong>About NANOPRIMER</strong></p>  <p align="justify">The Nanoprimer is an early-stage nanotherapeutic platform designed to disrupt the design and development of innovative therapeutics and improve outcomes for patients. The Nanoprimer potentially increases drug bioavailability or decreases unintended off-target effects in the liver, specifically hepatic toxicity. The platform is designed for use in combination with advanced therapeutics across multiple drug classes. The Nanoprimer is being developed through external collaborations and an internal proprietary pipeline.</p>  <p>Nanoprimer is an early-stage nanotherapeutic platform designed to unleash the potential of advanced therapeutics by addressing one of the most common structural limitations in modern medicine: liver uptake and extrahepatic delivery. As therapies become more complex&#8212;such as RNA, gene therapies, and advanced biologics&#8212;they are increasingly captured by the liver, limiting their ability to reach target tissues and reducing their effectiveness.</p>  <p>Nanoprimer transiently modulates this natural clearance, allowing more drug to circulate longer, reach its intended target, and reduce off-target liver exposure.This approach can both enhance the performance of existing therapies and unlock new therapeutic pathways that were previously not achievable.</p>  <p>Developed as a therapeutic companion platform, Nanobiotix is advancing this technology through strategic external collaborations alongside a proprietary internal pipeline of Nanoprimer-enabled assets.</p>  <p><strong>About NANOBIOTIX</strong></p>  <p align="justify">Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company&#8217;s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.</p>  <p align="justify">Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.</p>  <p align="justify">Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.</p>  <p align="justify">For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter</p>  <p align="justify"><strong>Disclaimer</strong></p>  <p align="justify"><em>This press release contains &#8220;forward-looking&#8221; statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company&#8217;s anticipates its financial resources will be adequate to support operations. Words such as &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;can&#8221;, &#8220;could&#8221;, &#8220;may&#8221;, &#8220;might&#8221;, &#8220;plan&#8221;, &#8220;potential&#8221;, &#8220;should&#8221; and &#8220;will&#8221; or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company&#8217; management&#8217;s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix&#8217;s business and financial performance, which include the risk that assumptions underlying the Company&#8217;s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix&#8217;s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under &#8220;Item 3.D. Risk Factors&#8221;, in Nanobiotix&#8217;s 2025 universal registration document filed with the AMF on March 31, 2026 under &#8220;chapter 1.5 Risk Factors&#8221;, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, which are available on the SEC&#8217;s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.</em></p> <table style="width:99%; border-collapse:collapse !important;;border-top: solid black 1pt ; border-collapse: collapse; "><tr><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><em>Nanobiotix</em></td></tr><tr><td style="max-width:50%; width:50%; min-width:50%;;border-bottom: solid black 1pt ; vertical-align: middle ; "><strong>Communications Department</strong><br ><em>Brandon Owens</em><br ><em>VP, Communications</em><br >+1 (617) 852-4835<br ><u>contact@nanobiotix.com</u></td><td style="max-width:50%; width:50%; min-width:50%;;border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; "><strong>Investor Relations Department</strong><br ><em>Joanne Choi</em><br ><em>VP, Investor Relations (US)</em><br >+1 (713) 609-3150<br >joanne.choi@nanobiotix.com<br ><br ><em>Ricky Bhajun</em><br ><em>Director, Investor Relations (EU)</em><br >+33 (0) 79 97 29 99<br ><u>investors@nanobiotix.com</u></td></tr><tr><td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><em>Media Relations</em></td></tr><tr><td style="vertical-align: middle ; "><br >France &#8211;<strong>HARDY</strong><br >Caroline Hardy<br >+33 06 70 33 49 50<br >carolinehardy@outlook.fr<br ><br ></td><td style="border-top: solid black 1pt ; vertical-align: top ; "><br >Global &#8211;<strong>uncapped</strong><br >Becky Lauer<br >+1 (646) 286-0057<br >uncappednanobiotix@uncappedcommunications.com</td></tr></table> <p id="gnw_attachments_section-header">     <strong>Attachment</strong> </p>  <ul id="gnw_attachments_section-items"><li>         2026-04-20 -- NBTX -- PreClin Nanoprimer Data @ AACR 2026 -- FINAL.pdf&#160;(https://ml.globenewswire.com/Resource/Download/e705bf4a-53e9-4e77-bac3-9ac40a6e1a3a)       </li></ul> <p></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
